This article is more than 5 years old. Information may no longer be current.

Analyst: Market for ophthalmic disease therapeutics will top $6 billion in 2009

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DUBLIN, Ireland — The worldwide market for drugs targeting ophthalmic diseases should top $3.65 billion this year and should reach $6.4 billion by 2009, according to a market research report.

The ophthalmic drug market is expected to grow at a compound rate of 11.9% annually, according to Research & Markets. Over the next 5 years, glaucoma will continue to be the most treated indication, accounting for more than 50% of market revenues, according to a report from the international market research firm, based here.

The report notes that the emergence of therapies to treat age-related macular degeneration and other retinal neovascular conditions will contribute substantially to the market’s growth.